AC 0176
Alternative Names: AC-0176; AC-176Latest Information Update: 12 Apr 2024
At a glance
- Originator Accutar Biotechnology
- Class Antineoplastics
- Mechanism of Action Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 05 Mar 2024 Accutar Biotechnology terminates a phase I trial in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO), due to changes in the subject benefit-risk ratio (NCT05241613)
- 08 Oct 2023 Accutar Biotechnology terminates a phase I trial for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in China (PO), due to changes in the subject benefit-risk ratio (NCT05673109)
- 23 Feb 2023 Phase-I clinical trials in Prostate cancer (Metastatic disease) in China (PO) (NCT05673109)